PubRank

Jan D Bos

Author PubWeight™ 72.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006 2.44
2 Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 2.12
3 Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004 1.95
4 How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2009 1.87
5 The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002 1.84
6 Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010 1.77
7 Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010 1.73
8 Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol 2011 1.71
9 Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol 2006 1.62
10 Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009 1.56
11 Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 2007 1.55
12 Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg 2011 1.41
13 UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol 2005 1.40
14 Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002 1.22
15 Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 1.22
16 Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002 1.14
17 Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004 1.09
18 The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009 1.07
19 Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol 2010 1.04
20 Overview of psoriasis. Dermatol Ther 2004 1.04
21 Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol 2006 0.97
22 Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol 2013 0.95
23 T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res 2011 0.92
24 Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res 2005 0.91
25 Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol 2011 0.90
26 Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002 0.90
27 Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol 2012 0.89
28 Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol 2003 0.89
29 T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. Arch Dermatol Res 2004 0.89
30 The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004 0.89
31 Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res 2004 0.88
32 Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One 2010 0.88
33 Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol 2008 0.87
34 Etanercept: an overview of dermatologic adverse events. Arch Dermatol 2011 0.87
35 The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol 2009 0.86
36 Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol 2011 0.86
37 Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 2004 0.86
38 Expression of terminal complement components by human keratinocytes. Mol Immunol 2007 0.85
39 Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol 2007 0.83
40 High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr 2013 0.83
41 Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol 2002 0.83
42 Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med 2010 0.82
43 Wet work and hand eczema in apprentice nurses; part I of a prospective cohort study. Contact Dermatitis 2013 0.82
44 Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J Allergy Clin Immunol 2006 0.82
45 Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch Dermatol Res 2004 0.82
46 Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatolog Treat 2011 0.82
47 Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res 2007 0.82
48 Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J Allergy Clin Immunol 2008 0.82
49 Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs. Exp Dermatol 2008 0.82
50 Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. Mol Immunol 2005 0.81
51 Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Exp Dermatol 2003 0.81
52 In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol 2004 0.80
53 Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002 0.80
54 Tertiary teledermatology: a systematic review. Telemed J E Health 2010 0.80
55 Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J Am Acad Dermatol 2011 0.79
56 Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol 2004 0.79
57 Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol 2009 0.79
58 Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther 2012 0.79
59 Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy. J Clin Rheumatol 2010 0.78
60 Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol 2008 0.77
61 Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. Arch Dermatol 2004 0.77
62 Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006 0.77
63 Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol 2004 0.77
64 UVB irradiation of normal human skin favors the development of type-2 T-cells in vivo and in primary dermal cell cultures. Photochem Photobiol 2002 0.77
65 Smallpox: what the dermatologist should know. Skinmed 2004 0.76
66 Filaggrin loss-of-function mutations and atopic dermatitis as risk factors for hand eczema in apprentice nurses: part II of a prospective cohort study. Contact Dermatitis 2013 0.76
67 A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin. Dermatology 2012 0.76
68 The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol 2004 0.76
69 Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat 2007 0.76
70 Proliferating prevalence of concepts and controversies in atopic eczema. J Cosmet Dermatol 2004 0.75
71 The use of patch tests in determining hypersensitivity to etanercept and infliximab. Arch Dermatol 2008 0.75
72 The atopic epidemic and the humidity hypothesis. J Cosmet Dermatol 2004 0.75
73 A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists. J Telemed Telecare 2010 0.75
74 Rudi Harold Cormane (1925-1987): a fabulous researcher and clinician. Clin Dermatol 2009 0.75
75 IL-4 expression by neutrophils in psoriasis lesional skin upon high-dose UVB exposure. Dermatology 2003 0.75
76 Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ. Arch Dermatol Res 2002 0.75
77 Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. Exp Dermatol 2010 0.75
78 Evaluation of a clinical guideline for the diagnoses of physical and chronic urticaria and angioedema. Acta Derm Venereol 2002 0.75